Lee Carrie B相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Fam-Trastuzumab-Deruxtecan and Osimertinib Combination to Target HER2 Driven Resistance in a Patient With NSCLC After Osimertinib Progression: Case Report

Fam-Trastuzumab-Deruxtecan联合奥希替尼治疗奥希替尼治疗进展后非小细胞肺癌患者的HER2驱动耐药：病例报告

期刊:JTO Clinical and Research Reports

影响因子:3.5

doi:10.1016/j.jtocrr.2025.100787

Hirata, Hailey M; Lee, Carrie B; Chen, Kevin Y

细胞生物学

发表日期：2025

文献求助收藏

North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era

后疫情时代北美癌症中心临床研究能力及基准评估

期刊:Jco Oncology Practice

影响因子:4.6

doi:10.1200/OP.24.00164

Kasner, Margaret; Fritsche, Angela H; Leong, Man Chong; Cameron, Kendra; Lee, Carrie B; Lin, Tara L; Lee, Ji-Hyun; Brogan, Frances; Kovak, Matthew R; Honeycutt, Hailey; Shaw, Kate; George, Thomas J

发表日期：2024

文献求助收藏

Coronary Artery Calcifications and Cardiac Risk After Radiation Therapy for Stage III Lung Cancer

III期肺癌放射治疗后冠状动脉钙化与心脏风险

期刊:International Journal of Radiation Oncology Biology Physics

影响因子:6.5

doi:10.1016/j.ijrobp.2021.08.017

Wang, Kyle; Malkin, Hayley E; Patchett, Nicholas D; Pearlstein, Kevin A; Heiling, Hillary M; McCabe, Sean D; Deal, Allison M; Mavroidis, Panayiotis; Oakey, Mary; Fenoli, Jeffrey; Lee, Carrie B; Klein, J Larry; Jensen, Brian C; Stinchcombe, Thomas E; Marks, Lawrence B; Weiner, Ashley A

发表日期：2022

文献求助收藏

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

黑色素瘤辅助治疗中伊匹木单抗引起的免疫不良事件（irAEs）、免疫抑制剂的使用及其与预后的关系：ECOG-ACRIN E1609 研究分析

期刊:Journal for ImmunoTherapy of Cancer

影响因子:10.6

doi:10.1136/jitc-2021-002535

Tarhini, Ahmad A; Kang, Ni; Lee, Sandra J; Hodi, F Stephen; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriet M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M

免疫/内分泌

发表日期：2021

文献求助收藏

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors

阿特珠单抗联合干扰素-α，或不联合贝伐珠单抗治疗转移性肾细胞癌和其他实体瘤患者的Ib期研究

期刊:Current Oncology

影响因子:3.4

doi:10.3390/curroncol28060455

Blank, Christian U; Wong, Deborah J; Ho, Thai H; Bauer, Todd M; Lee, Carrie B; Bene-Tchaleu, Fabiola; Zhu, Jing; Zhang, Xiaosong; Cha, Edward; Sznol, Mario

细胞生物学

发表日期：2021

文献求助收藏

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

辅助性伊匹木单抗（3 或 10 mg/kg）与高剂量干扰素α-2b治疗切除术后高危黑色素瘤的III期研究：北美多中心研究组 E1609

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.19.01381

Tarhini, Ahmad A; Lee, Sandra J; Hodi, F Stephen; Rao, Uma N M; Cohen, Gary I; Hamid, Omid; Hutchins, Laura F; Sosman, Jeffrey A; Kluger, Harriett M; Eroglu, Zeynep; Koon, Henry B; Lawrence, Donald P; Kendra, Kari L; Minor, David R; Lee, Carrie B; Albertini, Mark R; Flaherty, Lawrence E; Petrella, Teresa M; Streicher, Howard; Sondak, Vernon K; Kirkwood, John M

发表日期：2020

文献求助收藏

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

一项针对晚期实体瘤患者的Ib期研究，评估了NEDD8激活酶抑制剂pevonedistat联合多西他赛、卡铂和紫杉醇或吉西他滨的疗效。

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-018-0610-0

Lockhart, A Craig; Bauer, Todd M; Aggarwal, Charu; Lee, Carrie B; Harvey, R Donald; Cohen, Roger B; Sedarati, Farhad; Nip, Tsz Keung; Faessel, Hélène; Dash, Ajeeta B; Dezube, Bruce J; Faller, Douglas V; Dowlati, Afshin

发表日期：2019

文献求助收藏

Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy

III期非小细胞肺癌放疗后心脏毒性：剂量递增试验（70至90 Gy）的汇总分析

期刊:Journal of Clinical Oncology

影响因子:41.9

doi:10.1200/JCO.2016.70.0229

Wang, Kyle; Eblan, Michael J; Deal, Allison M; Lipner, Matthew; Zagar, Timothy M; Wang, Yue; Mavroidis, Panayiotis; Lee, Carrie B; Jensen, Brian C; Rosenman, Julian G; Socinski, Mark A; Stinchcombe, Thomas E; Marks, Lawrence B

细胞生物学

发表日期：2017

文献求助收藏

Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer

对接受剂量递增试验治疗的III期非小细胞肺癌患者进行三种类型心脏毒性的心脏剂量学分析

期刊:Radiotherapy and Oncology

影响因子:5.3

doi:10.1016/j.radonc.2017.10.001

Wang, Kyle; Pearlstein, Kevin A; Patchett, Nicholas D; Deal, Allison M; Mavroidis, Panayiotis; Jensen, Brian C; Lipner, Matthew B; Zagar, Timothy M; Wang, Yue; Lee, Carrie B; Eblan, Michael J; Rosenman, Julian G; Socinski, Mark A; Stinchcombe, Thomas E; Marks, Lawrence B

细胞生物学

发表日期：2017

文献求助收藏

Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.

LKB1 和 KRAS 的改变与脑转移风险：通过突变分析、拷贝数和基因表达对非小细胞肺癌进行全面表征

期刊:Lung Cancer

影响因子:4.4

doi:10.1016/j.lungcan.2014.08.013

Zhao Ni, Wilkerson Matthew D, Shah Usman, Yin Xiaoying, Wang Anyou, Hayward Michele C, Roberts Patrick, Lee Carrie B, Parsons Alden M, Thorne Leigh B, Haithcock Benjamin E, Grilley-Olson Juneko E, Stinchcombe Thomas E, Funkhouser William K, Wong Kwok-Kin, Sharpless Norman E, Hayes D Neil

细胞生物学

发表日期：2014

文献求助收藏